171 related articles for article (PubMed ID: 15766555)
1. C-reactive protein binds to the 3beta-OH group of cholesterol in LDL particles.
Taskinen S; Hyvönen M; Kovanen PT; Meri S; Pentikäinen MO
Biochem Biophys Res Commun; 2005 Apr; 329(4):1208-16. PubMed ID: 15766555
[TBL] [Abstract][Full Text] [Related]
2. Binding of low density lipoprotein (LDL) to C-reactive protein (CRP): a possible binding through apolipoprotein B in LDL at phosphorylcholine-binding site of CRP.
Nunomura W; Hatakeyama M
Hokkaido Igaku Zasshi; 1990 Sep; 65(5):474-80. PubMed ID: 2227796
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein inhibits in vitro oxidation of low-density lipoprotein.
Rufail ML; Ramage SC; van Antwerpen R
FEBS Lett; 2006 Oct; 580(22):5155-60. PubMed ID: 16962105
[TBL] [Abstract][Full Text] [Related]
4. C-reactive protein, anti-C-reactive protein antibodies and clinical atherosclerosis.
Rosenau BJ; Costenbader KH; Schur PH
Vasc Med; 2008 Feb; 13(1):25-8. PubMed ID: 18372435
[TBL] [Abstract][Full Text] [Related]
5. Interactions of C-reactive protein with low-density lipoproteins: implications for an active role of modified C-reactive protein in atherosclerosis.
Ji SR; Wu Y; Potempa LA; Qiu Q; Zhao J
Int J Biochem Cell Biol; 2006; 38(4):648-61. PubMed ID: 16376133
[TBL] [Abstract][Full Text] [Related]
6. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
Keleş T; Akar Bayram N; Kayhan T; Canbay A; Sahin D; Durmaz T; Ozdemir O; Aydoğdu S; Diker E
Anadolu Kardiyol Derg; 2008 Dec; 8(6):407-12. PubMed ID: 19103535
[TBL] [Abstract][Full Text] [Related]
7. Carbohydrate-binding properties of human neo-CRP and its relationship to phosphorylcholine-binding site.
Lee RT; Lee YC
Glycobiology; 2003 Jan; 13(1):11-21. PubMed ID: 12634320
[TBL] [Abstract][Full Text] [Related]
8. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.
Dornbrook-Lavender KA; Joy MS; Denu-Ciocca CJ; Chin H; Hogan SL; Pieper JA
Pharmacotherapy; 2005 Mar; 25(3):335-44. PubMed ID: 15843280
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of the binding of human C-reactive protein (CRP) to laminin.
Swanson SJ; McPeek MM; Mortensen RF
J Cell Biochem; 1989 May; 40(1):121-32. PubMed ID: 2745572
[TBL] [Abstract][Full Text] [Related]
10. Binding of human serum amyloid P-component to phosphocholine.
Christner RB; Mortensen RF
Arch Biochem Biophys; 1994 Nov; 314(2):337-43. PubMed ID: 7979374
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein and annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized low-density lipoprotein.
van Tits L; de Graaf J; Toenhake H; van Heerde W; Stalenhoef A
Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):717-22. PubMed ID: 15692104
[TBL] [Abstract][Full Text] [Related]
12. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
[TBL] [Abstract][Full Text] [Related]
13. Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol.
van der Harst P; Asselbergs FW; Hillege HL; Bakker SJ; Voors AA; van Veldhuisen DJ; van Gilst WH;
Am J Cardiol; 2007 Nov; 100(10):1548-51. PubMed ID: 17996517
[TBL] [Abstract][Full Text] [Related]
14. Site-directed mutagenesis of the phosphocholine-binding site of human C-reactive protein: role of Thr76 and Trp67.
Agrawal A; Lee S; Carson M; Narayana SV; Greenhough TJ; Volanakis JE
J Immunol; 1997 Jan; 158(1):345-50. PubMed ID: 8977209
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention.
Razzouk L; Muntner P; Bansilal S; Kini AS; Aneja A; Mozes J; Ivan O; Jakkula M; Sharma S; Farkouh ME
Am Heart J; 2009 Aug; 158(2):277-83. PubMed ID: 19619706
[TBL] [Abstract][Full Text] [Related]
16. Rationale for targeted rather than population based screening with C-reactive protein using the National Health and Nutrition Examination Survey (1999 to 2002).
Guttormsen BN; Stein JH; McBride PE; Cullen MW; Gangnon R; Keevil JG
Am J Cardiol; 2007 Oct; 100(7):1130-3. PubMed ID: 17884376
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients.
Yamada S; Yanagawa T; Sasamoto K; Araki A; Miyao M; Yamanouchi T
Metabolism; 2006 Jan; 55(1):67-71. PubMed ID: 16324921
[TBL] [Abstract][Full Text] [Related]
18. Native and modified C-reactive protein bind different receptors on human neutrophils.
Heuertz RM; Schneider GP; Potempa LA; Webster RO
Int J Biochem Cell Biol; 2005 Feb; 37(2):320-35. PubMed ID: 15474978
[TBL] [Abstract][Full Text] [Related]
19. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
20. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
Bays HE; Davidson M; Jones MR; Abby SL
Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
